Publication | Open Access

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

Drug TargetEngineeringTranslational BioinformaticsMedicinePharmacologyMultiomicsDifferential Clinical ActivityPathway AnalysisSystems BiologyMolecular DiagnosticsNovel TherapyDrug DiscoveryFda-approved Cdk4/6 Inhibitors